


Inhalation of LTI-03 modulates multiple targets in AILER a Phase 1b placebo-controlled clinical trial for IPF

<u>Cory M. Hogaboam</u>¹, BreAnne MacKenzie², Brecht Creyns¹, Yago Amigo Pinho Jannini-Sa¹, Ana Lucia Coelho¹, Poornima Mahavadi³, Brian Windsor¹, Sydney Kruger², Steve Shoemaker², Philip L Molyneaux⁴, Tanzira Zaman⁵, Tejaswini Kulkarni⁶, Collin Chia⁷, Nik Hirani⁸, Andreas Guenther³



¹Women's Guild Lung Institute, Cedars Sinai Medical Center, Los Angeles, CA, 90048; ²Aileron Therapeutics, Inc., Austin, TX, 78758; ³University of Giessen and Marburg Lung Center, Giessen, Germany, 35392; ⁴Royal Brompton Hospital Dovehouse St, London, United Kingdom, SW3 6JY; ⁵Pulmonary & Critical Care Medicine, Cedars Sinai Medical Center, Los Angeles, CA, 90048; ⁶Pulmonary, Allergy & Critical Care Medicine, University of Alabama Birmingham, Alabama, 35294; ⁷Launceston Respiratory and Sleep Center, Launceston General Hospital, Launceston, TAS, 7250; ⁸Edinburgh Lung Fibrosis Clinic, Royal Infirmary Edinburgh, UK, EH16 4SA

RATIONALE: Translational strategy for LTI-03 biomarker development



DATA: Ph1b cohort 1 safety and exploratory biomarker results

